Biogen (NASDAQ:BIIB) Price Target Raised to $245.00 at Canaccord Genuity Group

Biogen (NASDAQ:BIIB) had its price objective increased by investment analysts at Canaccord Genuity Group from $230.00 to $245.00 in a research note issued on Wednesday,MarketScreener reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Canaccord Genuity Group’s target price indicates a potential upside of 33.64% from the stock’s current price.

Several other equities analysts have also recently commented on BIIB. Sanford C. Bernstein reissued a “market perform” rating on shares of Biogen in a research report on Monday, February 9th. Wedbush increased their price target on Biogen from $178.00 to $187.00 and gave the company a “neutral” rating in a research report on Monday, February 9th. Stifel Nicolaus lifted their price target on Biogen from $202.00 to $214.00 and gave the stock a “buy” rating in a report on Friday, February 6th. BMO Capital Markets boosted their price objective on Biogen from $165.00 to $196.00 and gave the stock a “market perform” rating in a research report on Friday, February 6th. Finally, HC Wainwright raised their target price on Biogen from $194.00 to $228.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Twelve equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Biogen has a consensus rating of “Hold” and a consensus price target of $207.96.

Biogen Stock Performance

NASDAQ BIIB opened at $183.33 on Wednesday. Biogen has a 1 year low of $110.04 and a 1 year high of $202.41. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03. The firm has a market cap of $26.91 billion, a price-to-earnings ratio of 20.81, a PEG ratio of 1.49 and a beta of 0.15. The company has a fifty day moving average price of $186.19 and a 200-day moving average price of $170.98.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The company had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. During the same period last year, the firm earned $3.44 earnings per share. The firm’s revenue was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, equities research analysts predict that Biogen will post 15.83 EPS for the current fiscal year.

Insider Transactions at Biogen

In other news, insider Priya Singhal sold 2,660 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the transaction, the insider owned 8,043 shares in the company, valued at approximately $1,607,232.69. This represents a 24.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.18% of the stock is owned by corporate insiders.

Institutional Trading of Biogen

Institutional investors have recently modified their holdings of the business. World Investment Advisors raised its holdings in Biogen by 4.9% during the 4th quarter. World Investment Advisors now owns 6,739 shares of the biotechnology company’s stock valued at $1,186,000 after acquiring an additional 317 shares during the period. Corient Private Wealth LLC boosted its holdings in shares of Biogen by 18.0% in the fourth quarter. Corient Private Wealth LLC now owns 41,149 shares of the biotechnology company’s stock worth $7,245,000 after acquiring an additional 6,287 shares during the period. Hsbc Holdings PLC grew its position in shares of Biogen by 11.1% in the fourth quarter. Hsbc Holdings PLC now owns 503,832 shares of the biotechnology company’s stock valued at $88,838,000 after purchasing an additional 50,314 shares in the last quarter. Pure Financial Advisors LLC purchased a new position in shares of Biogen in the fourth quarter valued at $206,000. Finally, SHP Wealth Management bought a new stake in shares of Biogen during the 4th quarter valued at $39,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: FDA approval of a higher‑dose SPINRAZA regimen strengthens Biogen’s rare‑disease franchise and supports recurring revenue from an established product. This regulatory win is a near‑term catalyst for revenue stability and offsets some pipeline risk. US FDA approves higher-dose of Biogen’s genetic disorder drug
• Positive Sentiment: Biogen struck a definitive agreement to acquire Apellis for ~$5.6B in cash, adding two commercial drugs (EMPAVELI, SYFOVRE) and nephrology/immunology capabilities that could boost long‑term growth and diversify Biogen beyond MS and Alzheimer’s exposure. The deal includes contingent value rights (CVRs) tied to SYFOVRE sales. Biogen to buy Apellis Pharmaceuticals for $5.6 billion
• Positive Sentiment: Positive Phase II data for litifilimab in cutaneous lupus add to Biogen’s pipeline momentum, indicating incremental R&D upside beyond the transaction and SPINRAZA support. Pipeline wins help the investment narrative over the medium term. Biogen’s second positive Phase II litifilimab trial in CLE
• Neutral Sentiment: Apellis shares jumped sharply (100%+ intraday) after the offer — market evidence the deal values Apellis at a substantial premium; the move itself is a neutral signal for BIIB except insofar as it validates the target’s assets and the premium Biogen paid. Apellis Pharmaceuticals (APLS) Hits 2-Year High on 140% Upside from Biogen Merger
• Neutral Sentiment: Multiple sell‑side analysts maintained Hold ratings on BIIB, noting recent approvals and pipeline progress but flagging execution risks (Leqembi/Alzheimer’s exposure, MS erosion) — consensus remains cautious despite catalysts. Biogen: Spinraza HD Approval Supports but Does Not Transform Outlook
• Negative Sentiment: Biogen shares declined after the deal announcement as investors weighed the cash cost, the premium paid, and near‑term EPS dilution/return on investment uncertainty. The acquisition reduces near‑term financial flexibility and raises execution risk for integrating Apellis. Why Biogen Stock Sank While the Market Soared
• Negative Sentiment: An investor law‑firm investigation into the adequacy of Apellis’s sale process/price emerged, which could slow or complicate closing or create legal distractions — a governance/legal overhang to monitor. Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process
• Negative Sentiment: Some analysts warn the takeover caps upside from an M&A arbitrage view and that near‑term catalysts remain limited, tempering enthusiasm for BIIB until integration progress and SYFOVRE/EMPAVELI commercial traction are visible. Hold Rating on Apellis Reflects Biogen Takeover Cap on Upside and Limited Near-Term Catalysts

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.